IP Library › Granted Patent US 8,236,955
Granted Patent B2
US 8,236,955 · App. 13/158,734 · Granted Aug 7, 2012

Melanocortin receptor agonists

Assignee: LG Life Sciences Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,236,955
App. No.
13/158,734
Granted
Aug 7, 2012
Kind
B2
Abstract

The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Claims (1)

1. N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidin-3-yl]carbonyl}-5-[(4-methylpiperazin-1-yl)carbonyl]pyrrolidin-3-yl}-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropanamide or a salt thereof.

Assignments (1)
MERGER Recorded Sep 2, 2017
From: LG LIFE SCIENCES LTD.
To: LG CHEM, LTD.
Reel/Frame 043475/0619 →
Priority Claims (1)
KR 10-2008-0112403 · Nov 12, 2008 · national
Continuity (2)
Division 12615407 · Nov 10, 2009
Related Publication 20110237795A1 · Sep 29, 2011